Market recognition nr. 138/2024 of 03.10.2024 [active till 10.10.2024]

bsbiotechna offer

In connection with the implementation of the project entitled “Design and development of nanoparticle-RNA based drugs to be used in anti-cancer therapy with the construction of a nanoparticle platform for targeted delivery of therapeutic nucleic acids”, by BS Biotechna SA, within the framework of Contract No. 2022/ABM/06/00005-00 for funding of the Commercial Project under the Competition for the development of targeted or personalized medicine based on therapeutic products based on nucleic acids and small-molecule compounds, the Ordering Party is making a market discernment concerning The cost of purchasing a kit consisting of siRNA targeting MDMX mRNA (MDM4), Locus ID 4194, 3 unique siRNA duplexes (27-mer- 2 nmol each) (Locus ID 4194),control siRNA (27-mer, Negative control – 2 nmol) siRNA dissolution buffer, RNAase free – 2 mL

In order to submit an offer, please read the detailed content of the announcement included in the description of the service and send the completed offer form.

Udostępnij
Share
Scroll to Top